Goldar

Goldar is a prescription oral medication containing the synthetic steroid tibolone; each tablet delivers a standard therapeutic dose (strength not specified) of the active ingredient. It belongs to the hormone replacement therapy class and is marketed in the European Union. Tibolone acts on estrogen, progesterone, and androgen receptors to address hormonal changes associated with menopause. It is prescribed for women experiencing menopausal symptoms and for the management of estrogen deficiency.

Goldar is prescribed for the relief of menopausal symptoms and for the treatment of estrogen deficiency in post‑menopausal women, helping to restore hormonal balance.

- Reduction of hot flashes and night sweats, providing more comfortable temperature regulation. - Alleviation of vaginal dryness, itching, and discomfort, supporting sexual health. - Improvement of mood swings, irritability, and sleep disturbances commonly experienced during menopause. - Support for bone mineral density to help prevent osteoporosis associated with low estrogen levels. - Mitigation of general fatigue and decreased energy levels that often accompany hormonal transition.

Goldar, like other tibolone preparations, may cause a range of side effects that vary in frequency and severity.

Common: - Mild nausea, abdominal discomfort, or indigestion. - Transient headache or dizziness. - Breast tenderness or mild swelling. - Weight gain, fluid retention, or mild edema. - Mood changes such as irritability or mild depression.

Serious: - Development of blood clots such as deep‑vein thrombosis or pulmonary embolism. - Significant liver enzyme elevation indicating hepatic dysfunction. - Potential increase in hormone‑dependent tumor growth, including breast or endometrial cancer. - Severe allergic reaction with rash, itching, or swelling of the face.

When prescribing Goldar, clinicians consider several precautions to ensure safe use in women undergoing hormone replacement therapy.

- History of thromboembolic disorders such as deep‑vein thrombosis or stroke. - Active or past breast, uterine, or ovarian cancer. - Uncontrolled hypertension or cardiovascular disease. - Severe liver disease or abnormal liver function tests. - Pregnancy, lactation, or plans to become pregnant. - Smoking, especially in women over 35 years of age. - Known hypersensitivity to tibolone or any component of the formulation.

Goldar may interact with other medicines, affecting its efficacy or safety profile; certain combinations should be avoided while others require careful monitoring.

Avoid: - Concurrent use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) that may reduce tibolone levels. - Combination with anticoagulants (e.g., warfarin) that could increase clotting risk.

Use with caution: - Co‑administration with other hormonal agents such as estrogen or progestin may amplify hormonal effects. - Use together with lipid‑lowering drugs (e.g., statins) as tibolone can affect lipid metabolism. - Concurrent use with antidepressants, particularly SSRIs, may alter the management of mood‑related side effects.